continuous albuterol
Continuous nebulized albuterol (CAN) is a therapeutic technique used primarily in emergency departments (ED) and intensive care units (ICU) to treat severe, acute asthma exacerbations (status asthmaticus) that do not respond to standard intermittent treatments. 
Clinical Purpose and Efficacy
· Mechanism: It provides a constant flow of medication into the lungs, which may offer greater drug penetration, reduced bronchospasm, and more rapid, sustained relief.
· Effectiveness: Studies show CAN is at least as effective as frequent intermittent nebulization. It is associated with reduced hospital admission rates, shorter hospital stays, and a decreased need for mechanical ventilation.
· Efficiency: CAN is often used in busy EDs because it saves significant respiratory therapist time compared to administering multiple frequent intermittent doses.
Dosing Protocols
Dosing varies by institution and is often weight-based for pediatric patients.
· Pediatric Dosing: Common ranges include 10 mg/h to 15 mg/h for children. Recent 2025 research indicates that a lower starting dose of 10 mg/h provides clinical outcomes comparable to 15 mg/h and may lead to a shorter overall duration of therapy.
· Adult Dosing: Can range from 5 mg/h to 20 mg/h or higher depending on the severity of the attack and institutional guidelines.
Administration
· Equipment: CAN is typically administered using a large-volume nebulizer (LVN) or a small-volume nebulizer connected to an infusion pump.
· Monitoring: Patients receiving continuous albuterol require close clinical monitoring, including heart rate, respiratory rate, oxygen saturation, and serum potassium levels.
Safety and Side Effects
While generally safe, high-dose continuous albuterol can cause several adverse effects:
· Cardiovascular: Tachycardia (rapid heartbeat) is common; hypotension (low blood pressure) and arrhythmias are rarer.
· Metabolic: Hypokalemia (low potassium) and hyperglycemia (high blood sugar) can occur.
· Gastrointestinal: Nausea and vomiting are associated with higher initial doses, particularly in smaller pediatric patients.
· Neurological: Jitteriness, tremors, and hyperactivity.
0 comments